While pre-clinical studies for GC are not yet available, CAR-N therapy presents a promising new avenue for GC treatment, particularly when combined with GC immunosurveillance and immunomodulation strategies targeting the HER2 surface marker. Here, ERBB2 is linked to gastric cancer.